NCT01301898View on ClinicalTrials.gov

To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Mucopolysaccharidosis II
Interventions
DRUG

GC1111_0.5mg/kg

DRUG

GC1111_1.0mg/kg

DRUG

Elaprase_0.5mg/kg

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY